Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02004275
Recruitment Status : Suspended (DSMB recommendation to revise study design)
First Posted : December 9, 2013
Last Update Posted : May 8, 2018
National Cancer Institute (NCI)
Celgene Corporation
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology

No Study Results Posted on for this Study
  Recruitment Status : Suspended
  Estimated Primary Completion Date : August 2019
  Study Completion Date : No date given